<DOC>
	<DOC>NCT01490736</DOC>
	<brief_summary>The purpose of this study is to determine the safety of photodynamic therapy (PDT) with lemuteporfin topical solution (LTS) in healthy subjects and subjects with mild acne.</brief_summary>
	<brief_title>Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne</brief_title>
	<detailed_description>This is a sequentially staged (Stage 1-4), proof of concept study assessing the safety of photodynamic therapy (PDT) and lemuteporfin topical solution (LTS) in healthy subjects and subjects with mild acne. Approximately 12 subjects will be enrolled in Stage 1 in order to determine a maximum tolerated light dose following LTS application. Up to 90 subjects with mild acne will be enrolled in Stage 2 in order to assess the safety of PDT following a single LTS application. Up to 50 subjects will be enrolled in Stage 3 in order to assess the safety of PDT following repeat LTS applications. Up to 40 subjects will be enrolled into Stage 4 to assess multiple treatments of LTS-PDT.</detailed_description>
	<criteria>Stage 1 only: healthy subjects Stage 14: male or female subjects age 18 years or older Stage 2: subjects with sebum excretion rate of 4 or higher on forehead Stage 24: subjects with at least 2 inflammatory acne lesions on the forehead Stage 34: subjects with sebum excretion rate of 5 or higher on forehead Poor skin condition on back (Stage 1) or face (Stage 2 &amp; 3) Severe facial acne, acne fluminans/conglobata, or nodulocystic acne Stage 24: previous use of Diane35 within 6 months of Day 0, systemic acne treatment or systemic antibiotic treatment within 28 days of Day 0, topical acne treatment to the face within 14days of Day 0 or PDT to the face within 3 months of Day 0 Stage 24: previous treatment of isotretinoin or other oral retinoids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Acne</keyword>
	<keyword>Sebum gland disease</keyword>
</DOC>